Gnofam Mayi, Allshouse Amanda A, Stickrath Elaine H, Metz Torri D
Department of Obstetrics and Gynecology, University of Colorado Denver, Aurora, Colorado.
Department of Obstetrics and Gynecology, Maison Blanche's Hospital, University of Reims, Champagne-Ardenne, France.
Am J Perinatol. 2020 Jan;37(1):59-65. doi: 10.1055/s-0039-1696719. Epub 2019 Sep 6.
We aimed to assess whether marijuana legalization was associated with a difference in prevalence of prenatal use or an increase in incidence of adverse perinatal outcomes.
The present study is a retrospective cohort of September and October deliveries in the years 2012 through 2015 at a tertiary center in Colorado. Primary outcome of the study was use of marijuana, defined by self-report or biodetection. Secondary outcomes of the study included growth restriction, spontaneous preterm birth, stillbirth, preeclampsia, and neonatal or maternal death. Marijuana use prevalence was compared by year, and secondary outcomes between two periods, before and after the opening of the first recreational dispensary.
A total of 2,392 pregnant women were included (1,165 before legalization and 1,227 after). More women used marijuana over the period of legalization (trend = 0.01). Odds of marijuana use were higher after legalization versus before (adjusted odds ratio [aOR] = 1.8, 95% confidence interval [CI]: 1.2-2.6). Incidence of growth restriction was higher after legalization (2.9 vs. 5.1%, = 0.0084). This difference persisted after adjustment for ethnicity and other drugs in multivariable modeling (aOR = 1.9, 95%CI: 1.2-3.0).
The prevalence of prenatal marijuana use increased over the time of legalization. Further investigation into the population impact of legalization on obstetrical outcomes is warranted given the observed increase in growth restriction.
我们旨在评估大麻合法化是否与产前使用大麻的患病率差异或围产期不良结局的发生率增加有关。
本研究是一项对2012年至2015年9月和10月在科罗拉多州一家三级医疗中心分娩情况的回顾性队列研究。该研究的主要结局是使用大麻,通过自我报告或生物检测来定义。该研究的次要结局包括生长受限、自发性早产、死产、先兆子痫以及新生儿或孕产妇死亡。按年份比较大麻使用患病率,并比较第一家娱乐性大麻药房开业前后两个时期的次要结局。
总共纳入了2392名孕妇(合法化前1165名,合法化后1227名)。在大麻合法化期间使用大麻的女性更多(趋势=0.01)。合法化后使用大麻的几率高于合法化前(调整后的优势比[aOR]=1.8,95%置信区间[CI]:1.2-2.6)。合法化后生长受限的发生率更高(2.9%对5.1%,P=0.0084)。在多变量模型中对种族和其他药物进行调整后,这种差异仍然存在(aOR=1.9,95%CI:1.2-3.0)。
在大麻合法化期间,产前使用大麻的患病率有所上升。鉴于观察到生长受限有所增加,有必要进一步调查合法化对产科结局的人群影响。